首页> 外文期刊>Genetics and Molecular Research >Polymorphisms of the angiotensin II type 1 receptor gene affect antihypertensive response to angiotensin receptor blockers in hypertensive Chinese
【24h】

Polymorphisms of the angiotensin II type 1 receptor gene affect antihypertensive response to angiotensin receptor blockers in hypertensive Chinese

机译:血管紧张素Ⅱ1型受体基因的多态性影响高血压患者对血管紧张素受体阻滞剂的降压反应

获取原文
           

摘要

The renin-angiotensin-aldosterone system plays a key role in regulating blood pressure by maintaining vascular tone and the water/sodium balance. Many antihypertensive drugs target the renin-angiotensin-aldosterone system, but the effect differs considerably among hypertensive patients. We investigated whether genetic variants of the angiotensin II type 1 receptor are associated with blood pressure response to angiotensin II receptor blockers in hypertensive Chinese patients. After a 2-week single-blind placebo run-in period, 148 patients with mild-to-moderate primary hypertension received monotherapy with 80 mg/day telmisartan and then were followed up for 8 weeks. The 1166A/C, 573T/C, -810A/T, and -521C/T polymorphisms of the AT1R gene were determined through PCR and RFLP analysis. The relationship between these polymorphisms and changes in blood pressure was observed and evaluated after 8 weeks of treatment. Patients with the AT1R -521CC genotype had a significant reduction in diastolic blood pressure compared to those carrying the T allele. No significant reduction in blood pressure was found in individuals with the 1166A/C, 573T/C, or -810A/T polymorphisms of the AT1R gene. We conclude that only the AT1R -521CC genotype is associated with a significant decrease in blood pressure in response to telmisartan treatment in Chinese hypertensive patients.
机译:肾素-血管紧张素-醛固酮系统通过维持血管紧张度和水/钠平衡在调节血压中起关键作用。许多降压药以肾素-血管紧张素-醛固酮系统为靶标,但在高血压患者中其作用差异很大。我们调查了高血压中国患者中1型血管紧张素II受体的遗传变异是否与血压对血管紧张素II受体阻滞剂的反应有关。经过2周的单盲安慰剂磨合期后,对148例轻度至中度原发性高血压患者接受了80 mg /天替米沙坦的单药治疗,随后进行了8周的随访。通过PCR和RFLP分析确定了AT1R基因的1166A / C,573T / C,-810A / T和-521C / T多态性。治疗8周后观察并评估了这些多态性与血压变化之间的关系。与携带T等位基因的患者相比,具有AT1R -521CC基因型的患者的舒张压明显降低。在具有AT1R基因1166A / C,573T / C或-810A / T多态性的个体中,未发现血压显着降低。我们得出的结论是,在中国高血压患者中,根据替米沙坦治疗,只有AT1R -521CC基因型与血压显着降低有关。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号